Aragen Life Sciences has received validation from the SBTi for its sustainability targets.
The global CDMO has set a number of near-term and net-zero targtes, including:
- An overall net-zero target set for 2050
- Reducing absolute scope 1, 2 and 3 GHG emissions by 50.4% by 2033
- Reducing absolute scope 1, 2 and 3 GHG emissions by 90% by 2050
SBTi targets provide companies with a framework for reducing their emissions — all of which are in line with the 2015 Paris agreement.
The validation positions the company among the leaders in the climate action movement within the life sciences sector.
Aragen Life Sciences' CEO, Manni Kantipudi, commented: "This validation by the SBTi is more than just a recognition of our efforts; it's a critical step forward in our sustainability journey. These targets underscore our dedication to innovation, collaboration, and transparency in a holistic manner, while ensuring sustainability measures are in place as we work with the 400+ customers globally. We are determined to make a meaningful and measurable impact in our fight against climate change."
Shivaji Jadhav, VP & Head, EHS & Sustainability at Aragen added: “This approval is an endorsement of the rigorous efforts we’ve put into our sustainability initiatives. It underscores our responsibility to our planet and reinforces our commitment to leading by example in the industry.”
